statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024...

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted...

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the 'Company' or 'Aytu') (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its...

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or 'Aytu') (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that...

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Volume	4,018.00
52-Wk High	$3.50
52-Wk Low	$1.38

AYTU Aytu BioPharma Inc

About

Feed

News

Sentiment

Fundamentals